EU GMP Explained: A Practical Guide to EudraLex Volume 4

If you work in pharmaceutical manufacturing, quality assurance, or regulatory affairs within the EU, you've likely heard of EudraLex Volume 4. But knowing its name and truly understanding what it means for your daily operations are two very different things.

Many organisations follow good manufacturing practices (GMP) at a surface level. Their paperwork looks fine, their line runs smoothly, and they assume compliance is covered. But when an EU inspector walks through the door, gaps that were invisible on paper suddenly become very visible. That's where a strong working knowledge of EudraLex Volume 4 makes all the difference.

This guide breaks down what EudraLex Volume 4 is, how it's structured, which annexes are most critical, and how to translate its requirements into real, day-to-day compliance actions.

What Is EudraLex Volume 4?

EudraLex is the collection of rules and guidelines that govern medicinal products in the European Union. It is published by the European Commission and comprises 10 volumes, each covering a different area of pharmaceutical regulation.

Volume 4 is the one dedicated entirely to Good Manufacturing Practice (GMP). It sets out the detailed requirements for the manufacture, control, and release to market of medicinal products, both for human and veterinary use.

It translates EU legislation, specifically Commission Directive (EU) 2017/1572 for human medicinal products and Directive 91/412/EEC for veterinary products, into practical, operational expectations. These are the standards EU GMP inspectors use when auditing your manufacturing site.

Crucially, Volume 4 is not a static document. It is regularly revised to keep up with advances in technology, digital systems, and the complexities of the global supply chain. If your compliance approach treats it as something you read once and file away, that's a problem.

How EudraLex Volume 4 Differs from the Other Volumes

To understand why Volume 4 matters so much to manufacturing professionals, it helps to know what the other volumes cover:

• Volumes 1 and 5 deal with the legislative frameworks for human and veterinary medicinal products, respectively.
• Volumes 2 and 6 cover regulatory submission and application procedures.
• Volumes 3 and 7 provide scientific guidelines.
• Volume 9 covers pharmacovigilance, or drug safety monitoring.
• Volume 10 focuses on clinical trials guidance.

None of these directly tells you how to run your manufacturing site. Volume 4 does. It is the operational reference point for production teams, quality control departments, supply chain managers, and anyone involved in the physical making and releasing of medicines. If your role touches manufacturing or API supply, Volume 4 is your primary benchmark.

EU GMP certification is the real-world outcome of everything EudraLex Volume 4 demands. 

A step-by-step breakdown for EU and US companies from gap analysis to certificate issuance.

→ Read: How To Get GMP Certified: A Step-by-Step Guide For EU And US Companies

How EudraLex Volume 4 Is Structured

Volume 4 is divided into three main parts, supported by annexes that delve deeper into specific manufacturing areas.

Part I covers the core GMP requirements for finished medicinal products. This includes the pharmaceutical quality system, personnel responsibilities, premises and equipment standards, documentation practices, production controls, quality control, outsourced activities, complaint and recall handling, and internal audits.

Part II focuses specifically on active pharmaceutical ingredients (APIs) used as starting materials. Its requirements are aligned with ICH Q7, the international standard for API quality management. This section is essential for any manufacturer or supplier involved in the API supply chain.

Part III is a reference section containing supplementary guidance, interpretative documents, Q&A resources, and templates issued by the EMA and the European Commission. It helps clarify how to apply the rules in practice.

Beyond the three parts, EudraLex Volume 4 includes annexes that address specific product types, technologies, and operational contexts.

The Key Annexes of EudraLex Volume 4, And Why They Matter

Not all annexes carry equal weight. Some consistently attract more attention from regulators, quality professionals, and compliance teams because they address high-risk or fast-evolving areas of pharmaceutical manufacturing. Here are the ones you need to know well.

Annex 1, Manufacture of Sterile Medicinal Products

Annex 1 governs the manufacture of sterile products and was significantly revised in 2022. The revision introduced a major new requirement: a formalised Contamination Control Strategy (CCS). This means that contamination risk must now be actively managed across the entire product lifecycle, not just caught through end-product testing.

Compliance with Annex 1 requires:

• A documented CCS that covers facilities, utilities, operations, and monitoring
• Risk-based cleanroom classification and environmental monitoring programs
• Robust aseptic technique training and behaviour monitoring
• Validated sterilisation methods appropriate to the product and container

Sterile manufacturing is one of the most scrutinised areas during EU GMP inspections. If your site makes sterile products and your CCS isn't fully documented and operational, this should be your immediate priority.

Annex 11, Computerised Systems

As pharmaceutical operations become more digital, Annex 11 has become one of the most referenced parts of Volume 4. It sets out GMP expectations for any computerised system used in a GMP environment, from manufacturing execution systems (MES) and laboratory information management systems (LIMS) to electronic quality management systems (eQMS).

Key requirements include:

• System validation across the full lifecycle (not just at initial installation)
• Data integrity controls, including audit trails, access management, and electronic signatures
• Supplier and vendor oversight for third-party systems
• Risk-based classification of computer systems by their impact on product quality

Annex 11 is currently under revision, with a public consultation ongoing. A proposed new Annex 22 on artificial intelligence is also in development. These changes reflect the EU's serious commitment to digital compliance and AI governance in pharma manufacturing.

Annex 13, Investigational Medicinal Products (IMPs)

Annex 13 applies specifically to medicinal products used in clinical trials. It sets GMP requirements for the manufacturing, packaging, labelling, and supply of investigational products.

Organisations moving a product from the trial stage to commercial manufacturing need to ensure their IMP processes are already operating at a GMP level comparable to commercial standards. Annex 13 is particularly relevant for contract manufacturers and sponsors managing complex global clinical supply chains.

Annex 15, Qualification and Validation

Annex 15 provides detailed guidance on qualifying facilities, equipment, and utilities, as well as validating processes, cleaning procedures, computerised systems, and analytical methods. The approach here is explicitly risk-based and lifecycle-oriented.

What this means in practice:

• Qualification and validation don't end after initial approval. They must be maintained and reviewed whenever changes occur.
• Cleaning validation must be robust and scientifically sound, with clear acceptance criteria.
• Annex 15 cross-references Annex 11, so your validation approach for computerised systems must align with both annexes.

Annex 16, Qualified Person (QP) Certification and Batch Release

Annex 16 governs the role of the Qualified Person (QP) and the process of batch certification and release in the EU and EEA. Every batch of a medicinal product must be certified by a QP before it can be placed on the market.

The QP is responsible for ensuring that each batch is manufactured and tested in accordance with EU GMP requirements. In the context of global supply chains and imported products, the QP must also be able to confirm compliance for materials and processes that may sit outside their direct control.

Annex 19, Reference and Retention Samples

Annex 19 addresses the requirements for taking, storing, and retaining samples from each batch, both reference and retention samples. These samples serve as your safety net for investigations, complaints, stability challenges, and recall readiness.

Failures in this area are red flags during audits. Traceability of the sample chain and clear retention timelines must be maintained and documented.

Annex 21, Importation of Medicinal Products

Annex 21 outlines GMP expectations for importing medicinal products into the EU or EEA. It is increasingly relevant given how much of the pharmaceutical supply chain now spans multiple countries and continents.

Under Annex 21, the importer (as the Manufacturing Import Authorisation or MIA holder) must ensure that all documentation, batch records, and QP certification meet EU GMP standards, regardless of where the product was originally manufactured.

Practical Compliance Tips for EudraLex Volume 4

Reading Volume 4 is one thing. Actually embedding it into your operations is another. Here are four areas where compliance either holds together or falls apart.

1. Build Risk-Based Thinking Into Your Daily Operations

Volume 4 explicitly calls for risk-based decision-making, in alignment with ICH Q9. This isn't just a box-ticking exercise; it means formally assessing risk at every meaningful step, from introducing a new piece of equipment to changing a supplier.

A practical starting point: use tools like Failure Mode and Effects Analysis (FMEA) when evaluating process changes. Document the assessment. Show the link between identified risks, control measures, and GMP expectations. Auditors will ask for this evidence.

2. Align Your Quality System with ICH Q10

Chapter 1 of Volume 4 describes a Pharmaceutical Quality System (PQS) modelled on ICH Q10, a lifecycle-oriented, knowledge-driven quality management framework. Rather than running disconnected SOPs and training modules, your organisation should map everything into a coherent PQS.

Connect your document control, change control, deviation handling, CAPA processes, and training programs so they all feed into and support each other. When an auditor asks how a cleaning procedure change triggered retraining and documentation updates, you should have a clear, traceable answer.

3. Prepare for Audits Using Volume 4 as Your Checklist

EU auditors use Volume 4 as their reference. So should you. Build your internal audit checklists around the structure of Part I chapters, Personnel, Premises and Equipment, Documentation, Production, Quality Control, alongside the relevant annexes for your specific operations.

Running a mock audit before a real inspection is one of the most effective ways to find gaps. Walk through your documentation control system: check revision histories, signature authenticity, and archival retrieval. Map what you find to Chapter 4 expectations.

4. Get Your Digital Systems in Order

If you use any computerised systems in a GMP environment, and almost everyone does , Annex 11 applies. Start by building a complete inventory of all GMP-relevant systems and classifying them by their risk level based on their impact on product quality or data integrity.

For each high-risk system, ensure that:

• Validation covers installation, operational, and performance qualification (IQ, OQ, PQ), plus periodic review
• Audit trails are active, protected, and regularly reviewed
• User access controls are documented and limited by role
• Electronic records and signatures meet EU GMP requirements

An electronic QMS that centralises document control, training records, CAPAs, deviations, and audit management in a single validated platform is one of the most practical ways to meet Annex 11 expectations while keeping your quality system manageable.

Digital GMP compliance does not stop at Annex 11.

AI is already reshaping GMP standards across pharma operations and regulators are paying attention.

→ Read: AI & GMP Standards In Pharma Operations

Why EudraLex Volume 4 Is Only Getting More Important

The regulatory landscape in the EU is not standing still. The ongoing revision of Chapter 4 (Documentation) and Annex 11 (Computerised Systems), combined with the proposed Annex 22 on artificial intelligence, signals that digital compliance will only grow in scope and complexity.

Organisations that treat Volume 4 as a living framework, something they continuously monitor, update their systems against, and train their teams on, will be far better positioned than those who only look at it when an inspection is coming.

Final Thoughts

EudraLex Volume 4 is the manufacturing backbone of EU pharmaceutical regulation. It tells you how products must be made, controlled, and released. It covers everything from sterile manufacturing and API quality to digital systems and batch certification. And it applies to every organisation that manufactures, imports, or supplies medicinal products for the EU market.

Getting it right doesn't require reading every line of every annex in isolation. It requires mapping your operations to its structure, embedding risk-based thinking into your quality system, training your teams on what the requirements actually mean in practice, and staying alert to updates.

FAQs

Q1: What is EudraLex Volume 4 used for? 

EudraLex Volume 4 sets out the Good Manufacturing Practice (GMP) guidelines for the manufacture of human and veterinary medicinal products in the EU. It is used by manufacturers, quality teams, and regulators as the operational standard for pharmaceutical production, quality control, and batch release.

Q2: How many annexes does EudraLex Volume 4 have? 

EudraLex Volume 4 contains over 20 annexes, each covering a specific manufacturing area or product type. Key annexes include Annex 1 (sterile products), Annex 11 (Computerised systems), Annex 15 (qualification and validation), Annex 16 (QP and batch release), and Annex 21 (importation).

Q3: What is the difference between EudraLex Volume 4 Part I and Part II? 

Part I covers GMP requirements for finished medicinal products, including quality systems, production, and documentation. Part II focuses on active pharmaceutical ingredients (APIs) used as starting materials, and its requirements are aligned with the international ICH Q7 guideline.

Q4: Is EudraLex Volume 4 legally binding? 

EudraLex Volume 4 is based on EU legislation and serves as the regulatory reference for GMP inspections, manufacturing authorizations, and batch certification in the EU and EEA. Non-compliance can lead to regulatory findings, import bans, or market withdrawal of products.

Q5: How often is EudraLex Volume 4 updated? 

EudraLex Volume 4 is updated on an ongoing basis as regulations, technologies, and industry practices evolve. Recent examples include the 2022 revision of Annex 1 and ongoing consultations on revisions to Annex 11 and a new proposed Annex 22 on artificial intelligence in pharmaceutical manufacturing.